LCZ696
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Heart Failure With Reduced Ejection Fraction
Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Trial Timeline
Oct 16, 2014 → Dec 28, 2017
NCT ID
NCT02226120About LCZ696
LCZ696 is a phase 3 stage product being developed by Novartis for Chronic Heart Failure With Reduced Ejection Fraction. The current trial status is completed. This product is registered under clinical trial identifier NCT02226120. Target conditions include Chronic Heart Failure With Reduced Ejection Fraction.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02389933 | Pre-clinical | Completed |
| NCT03909295 | Phase 3 | Terminated |
| NCT02661217 | Approved | Completed |
| NCT02226120 | Phase 3 | Completed |
| NCT01922089 | Phase 2 | Completed |
| NCT01621633 | Phase 2 | Completed |
| NCT01593787 | Phase 3 | Completed |
| NCT00913653 | Phase 2 | Completed |
| NCT01569815 | Phase 1 | Completed |
Competing Products
20 competing products in Chronic Heart Failure With Reduced Ejection Fraction
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |